This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Raptor Pharmaceuticals And DaVita Clinical Research Launch Screening Program To Identify Patients With Late Onset Nephropathic Cystinosis

NOVATO, Calif., Oct. 23, 2013 (GLOBE NEWSWIRE) -- Raptor Pharmaceutical Corp. (Nasdaq:RPTP) and DaVita Clinical Research ® (DCR ®) (NYSE:DVA) today announced a collaboration to screen blood samples from patients with end-stage renal disease (ESRD) in an effort to identify patients with unrecognized late-onset nephropathic cystinosis.

DCR will supply blood samples with clinical data annotation from DCR's biorepository of over four thousand patients with ESRD. The screening effort will employ high-throughput genetic sequencing of the cystinosin, lysosomal cystine transporter (CTNS) gene, mutations of which result in cystinosis. Results of the collaboration may reveal new insights into the prevalence of missed late-onset cystinosis in this at-risk patient population.

"Today, most nephropathic cystinosis patients are identified in infancy by pediatric nephrologists, yet, as with many genetic diseases, later-onset patients have been identified where the clinical manifestations of cystinosis may go unrecognized well into adulthood," noted Christopher M. Starr, Ph.D., Raptor's chief executive officer. "We believe these late-onset patients are likely to present with ESRD as adults and this screening program, initiated with this collaboration, may help adult nephrologists, many of whom are unfamiliar with the late onset form of the disease, identify patients who suffer from cystinosis."

The CTNS gene is responsible for coding for the protein cystinosin, which is responsible for transporting the amino acid cystine out of the lysosome in cells. The accumulation of cystine is toxic to every cell, and can therefore affect all tissues and organs in the body, most notably the kidneys.

"Nephropathic cystinosis is such a rare disease that it is likely that some cases have not been characterized in the adult population," said Amy Young, vice president and general manager of DaVita Clinical Research. "Our biorepository was designed and collected to enable this type of discovery and we are pleased to embark on a project that has the potential to improve clinical outcomes for ESRD patients."

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG

Markets

DOW 18,041.54 -190.48 -1.04%
S&P 500 2,104.20 -21.86 -1.03%
NASDAQ 5,032.7510 -56.6110 -1.11%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs